Home › NCT05736198

Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subjects with potentially difficult airways who require awake fiberoptic intubations will be identified from the OR schedule and the pre-operative clinic workups.

Exclusion Criteria:

* Anyone who does not meet the inclusion criteria

About the study

The purpose of this study is to examine the effects of different sedation drugs used for the awake fiberoptic intubation procedure. Benzodiazapines and narcotics (such as midazolam and fentanyl) are standard drugs used for sedation during awake fiberoptic intubation. Dexmedetomidine, midazolam, and fentanyl are approved by the Food and Drug Administration (FDA) procedural sedation. These drugs might be given to the patient regardless of their participation in the study.

In addition to midazolam and fentanyl study subjects will also receive either dexmedetomidine or a placebo (a salt solution that contains no drug). It is believed that dexmedetomidine will not slow down breathing as much as the combination of the valium-like drug and narcotic. In our study, we are trying to determine if this is the best drug for sedation during an awake fiberoptic procedure.

What is being tested

• Dexmedetomidine (drug)

Sponsor: University of Illinois at Chicago · Participants: 96 · Started: Aug 12, 2024

Contact the study team

• Alexandra Barabanova, MS · Phone: (312)355-5733

Official record on ClinicalTrials.gov — NCT05736198

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.